Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Black on the Developments in the Field of Immunotherapy for Bladder Cancer

August 25th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses future developments being made in the field of immunotherapy for patients with bladder cancer.

Reduced-Dose Cabazitaxel Shows Efficacy in mCRPC

August 25th 2017

Results from the PROSELICA trial showed that 20 mg/m2 of cabazitaxel (Jevtana) was as safe and effective as the 25 mg/m2 dose for postdocetaxel patients with metastatic castration-resistant prostate cancer.

Lead Investigator Discusses Atezolizumab/Bevacizumab in mRCC

August 25th 2017

Michael B. Atkins, MD, discusses the latest IMmotion150 findings and additional developments with immunotherapy in mRCC.

Dr. Nanus Discusses Early Stage Kidney Cancer Treatment

August 25th 2017

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment for patients with early-stage kidney cancer.

Dr. Campbell on the Future of the Management of RCC

August 24th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the future of the treatment management for patients with renal cell carcinoma (RCC).

Expert Discusses Impact of Muscle-Invasive Bladder Cancer Guidelines

August 24th 2017

The guidelines provide evidence-based recommendations on staging, neoadjuvant and adjuvant chemotherapy, radical cystectomy, urinary diversion, perioperative surgical management, and pelvic lymphadenectomy.

Update Offers New Insight on Atezolizumab/Bevacizumab Benefit in RCC

August 24th 2017

The combination of frontline atezolizumab and bevacizumab demonstrated superior efficacy compared with sunitinib or atezolizumab monotherapy in patients with advanced renal cell carcinoma.

Dr. Hammers on Next Steps with Immunotherapy in RCC

August 24th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).

Dr. Gupta on PD-L1 as a Biomarker in Kidney Cancer

August 23rd 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses PD-L1 as a biomarker in kidney cancer.

Dr. Feldman Discusses Metabolomic Findings in Prostate Cancer

August 23rd 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses metabolomic findings in prostate cancer.

Expert Discusses Next Steps for Durvalumab in Bladder Cancer

August 23rd 2017

Peter Black, MD, discusses the latest on durvalumab and other ongoing developments in the field of bladder cancer.

Dr. Campbell on Radical Nephrectomy in RCC

August 22nd 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the role of radical nephrectomy according to the guidelines for patients with renal cell carcinoma (RCC).

Expert Discusses Robotic Surgery in RCC

August 22nd 2017

Ketan K. Badani, MD, discusses the benefits of robotic surgery in RCC and use of the technique among urologists.

Dr. Badani Discusses the Adoption of Robotic Kidney Surgery

August 21st 2017

Ketan K. Badani, MD, professor of urology at Mount Sinai Hospital, discusses the adoption of robotic surgery in kidney cancer.

Dr. Choyke Discusses the Challenges With MRI in Prostate Cancer

August 21st 2017

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses the challenges with MRI in prostate cancer.

Dr. Choueiri on the Biology of the CABOSUN Trial for RCC

August 21st 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).

Dr. Feldman on Remaining Challenges With Biomarkers in Prostate Cancer

August 18th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses the remaining challenges with biomarkers in prostate cancer.

Dr. Black on Selecting Immunotherapy Agents in Bladder Cancer

August 18th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses selecting immunotherapy agents in bladder cancer.

Dr. Ornstein on Challenges With Immunotherapy in RCC

August 17th 2017

Moshe Ornstein, MD, staff, Cleveland Clinic, discusses the challenges surrounding immunotherapy for patients with renal cell carcinoma.

FDA Approval Sought for Frontline Cabozantinib in RCC

August 16th 2017

A supplemental new drug application has been submitted to the FDA for cabozantinib for previously untreated patients with advanced renal cell carcinoma.